Semaglutide slowed biological aging in a randomized trial
In a randomized trial of 84 adults with HIV, the drug behind Ozempic and Wegovy slowed epigenetic aging. The authors are quick to say this is not an anti-aging drug.
- In a 32-week randomized trial of 84 adults with HIV-associated lipohypertrophy, semaglutide slowed epigenetic aging.
- The PhenoAge clock read 4.9 years lower, PCGrimAge 3.1 years lower, and DunedinPACE showed a roughly 9 percent slower pace of aging.
- This was a post hoc analysis, meaning it was not the question the trial was built to answer, on a modest sample in an HIV-specific cohort.
- The researchers themselves say semaglutide is not an anti-aging drug and that larger studies are needed.
Can a weight-loss injection slow down aging? According to a new randomized trial, in one narrow group of patients it appears it can, but the answer is far smaller and far more grounded than the headlines suggest.
The paper, titled “Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy”, was published in Nature Communications, listed in the PubMed database in May of this year, and only picked up wider media attention in mid-July. Semaglutide is the active substance in Ozempic and Wegovy, so attention was guaranteed the moment the word “aging” appeared.
What did the researchers actually measure?
The trial was randomized, double-blind and placebo-controlled, phase 2b, running for 32 weeks. It involved 84 adults with HIV-associated lipohypertrophy: 45 received semaglutide and 39 received a placebo. The research was led by Michael J. Corley and Grace A. McComsey.
Biological age was measured using epigenetic clocks. These are algorithms that estimate the age of the body through DNA methylation, chemical marks that attach to the genome over a lifetime and shift their pattern. The idea is simple: calendar years pass at the same rate for everyone, biological years do not have to.
The numbers looked like this. The PhenoAge clock in the semaglutide group read 4.9 years lower. PCGrimAge was 3.1 years lower and GrimAge V2 was 2.3 years lower. DunedinPACE, which measures not age but the speed of aging, showed a roughly 9 percent slower pace.
It sounds impressive, and it is, as a signal. But each of those clocks measures a slightly different thing, so the differences do not add up to “a body five years younger”.
Why the authors themselves pump the brakes
This is the part that usually gets lost in the retelling. The epigenetic aging analysis was post hoc, meaning it was run afterwards, inside a trial designed to answer a different question. Findings like that are useful as a signpost for the next study, not as proof.
The limitations the authors list themselves run in order: post hoc design, a modest sample, an HIV-specific cohort and a follow-up of just 32 weeks. That last item may be the most important. Eight months is short for any claim about aging, a process measured in decades.
It is also worth noting that participants had lipohypertrophy, a build-up of fat tissue linked to HIV infection and its therapy. In this group, the loss of visceral fat and the drop in inflammation are expected to be large, which raises the question of how far the result carries over to a healthy person who might take the drug just in case.
The researchers were explicit: semaglutide is not an anti-aging drug and larger studies are needed before any firm conclusions. That is not a diplomatic sentence tacked onto the end of a paper, it is the condition for reading the whole finding.
The practical takeaway is modest but honest. This is the first clinical hint that an existing drug can touch the biology of aging in humans, and that matters. It is not a prescription, not an indication and not a reason for anyone to put themselves on a therapy meant for diabetes and obesity without a doctor and a clear medical picture.
What would convince you that something truly slows aging: a number on an epigenetic clock, or years of life that genuinely feel different?
